Federal Register: July 7, 2003 (Volume 68, Number 129)
DOCID: FR Doc 03-16954
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket ID: [Docket No. 2003D-0209]
ACTION: Reports and guidance documents; availability, etc.:
DOCUMENT ACTION: Notice.
Guidance for Industry and FDA Staff on Class II Special Controls Guidance Document; Breath Nitric Oxide Test System; Availability
DATES: Submit written or electronic comments on agency guidances at any time.
The Food and Drug Administration (FDA) is announcing the availability of the guidance entitled ``Class II Special Controls Guidance Document: Breath Nitric Oxide Test System.'' This guidance describes a means by which the breath nitric oxide test system may comply with the requirement of special controls for class II devices. Elsewhere in this issue of the Federal Register, FDA is publishing a final rule to classify the breath nitric oxide test system into class II (special controls). This guidance is effective immediately as the special control for the breath nitric oxide test system, but it remains subject to comment in accordance with the agency's good guidance practices (GGPs).
Medical devices—; Breath nitric oxide text system; Class II special controls,
Elsewhere in this issue of the Federal Register, FDA is publishing a final rule classifying the breath nitric oxide test system into class II (special controls) under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360c(f)(2)). This guidance document will serve as the special control for the breath nitric oxide test system device. Section 513(f)(2) of the act provides that any person who submits a premarket notification under section 510(k) of the act (21 U.S.C. 360(k)) for a device that has not previously been classified may, within 30 days after receiving an order classifying the device in class III under section 513(f)(1) of the act, request FDA to classify the device under the criteria set forth in section 513(a)(1) of the act. FDA shall, within 60 days of receiving such a request, classify the device by written order. This classification shall be the initial classification of the device. Within 30 days after the issuance of an order classifying the device, FDA must publish a notice in the Federal Register announcing such classification. Because of the timeframes established by section 513(f)(2) of the act, FDA has determined, under Sec. 10.115(g)(2) (21 CFR 10.115(g)(2)), that it is not feasible to allow for public participation before issuing this guidance as a final guidance document. Therefore, FDA is issuing this guidance document as a level 1 guidance document that is immediately in effect. FDA will consider any comments that are received in response to this notice to determine whether to amend the guidance document. II. Significance of Guidance
This guidance is being issued consistent with FDA's GGPs regulation (Sec. 10.115). The guidance represents the agency's current thinking on the breath nitric oxide test system. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute and regulations. III. Paperwork Reduction Act of 1995
This guidance contains information collection provisions that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA) (44 USC 35013520). The collections of information addressed in the guidance document have been approved by OMB in accordance with the PRA under the regulations governing premarket notification submissions (21 CFR part 807, subpart E, OMB control number 09100120). The labeling provisions addressed in the guidance have been approved by OMB under the PRA under OMB control number 09100485.
Interested persons may, at any time, submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments regarding the guidance document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. V. Electronic Access
To receive ``Class II Special Controls Guidance Document: Breath Nitric Oxide Test System'' by fax, call the CDRH FactsOnDemand system at 8008990381 or 3018270111 from a touchtone telephone. Press 1 to enter the system. At the second voice prompt, press 1 to order a document. Enter the document number (1211) followed by the pound sign ([numsign]). Follow the remaining voice prompts to complete your request.
Persons interested in obtaining a paper copy of the guidance may
also do so by using the Internet. CDRH maintains an entry on the
Internet for easy access to information including text, graphics, and
files that may be downloaded to a personal computer with Internet access. Updated on a
regular basis, the CDRH home page includes device safety alerts, Federal Register reprints, information on premarket submissions (including lists of approved applications and manufacturers' addresses), small manufacturer's assistance, information on video conferencing and electronic submissions, Mammography Matters, and other deviceoriented information. The CDRH web site may be accessed at http://www.fda.gov/cdrh. A search capability for all CDRH guidance documents is available at http://www.fda.gov/cdrh/guidance.html. Guidance documents are also available on the Division of
Dockets Management Internet site at http://www.fda.gov/ohrms/dockets.
Dated: June 23, 2003.
Linda S. Kahan,
Deputy Director, Center for Devices and Radiological Health. [FR Doc. 0316954 Filed 7303; 8:45 am]
BILLING CODE 416001S
FOR FURTHER INFORMATION CONTACT
Jean Cooper, Center for Devices and Radiological Health (HFZ440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 3015941243.